JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $31

Benzinga Newsdesk www.benzinga.com Negative 81.5%

Neg 81.5% Neu 0% Pos 0%

JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price target from $36 to $31.